
Vicore Pharma Holding AB
STO:VICO

Intrinsic Value
The intrinsic value of one
VICO
stock under the Base Case scenario is
3.92
SEK.
Compared to the current market price of 6.4 SEK,
Vicore Pharma Holding AB
is
Overvalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Vicore Pharma Holding AB
Fundamental Analysis


Revenue & Expenses Breakdown
Vicore Pharma Holding AB
Balance Sheet Decomposition
Vicore Pharma Holding AB
Current Assets | 1.2B |
Cash & Short-Term Investments | 1.2B |
Receivables | 14.4m |
Other Current Assets | 32.7m |
Free Cash Flow Analysis
Vicore Pharma Holding AB
SEK | |
Free Cash Flow | SEK |
Earnings Waterfall
Vicore Pharma Holding AB
Revenue
|
109.3m
SEK
|
Operating Expenses
|
-303.5m
SEK
|
Operating Income
|
-194.2m
SEK
|
Other Expenses
|
25.6m
SEK
|
Net Income
|
-168.6m
SEK
|
VICO Profitability Score
Profitability Due Diligence
Vicore Pharma Holding AB's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Score
Vicore Pharma Holding AB's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
VICO Solvency Score
Solvency Due Diligence
Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Score
Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VICO Price Targets Summary
Vicore Pharma Holding AB
According to Wall Street analysts, the average 1-year price target for
VICO
is 31.17 SEK
with a low forecast of 15.15 SEK and a high forecast of 40.86 SEK.
Dividends
Current shareholder yield for VICO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VICO
stock under the Base Case scenario is
3.92
SEK.
Compared to the current market price of 6.4 SEK,
Vicore Pharma Holding AB
is
Overvalued by 39%.